Nabriva registers $92 million of stock for initial public sale of ADSs

Bookrunners Leerink, RBC, co-managers Needham, Wedbush PacGrow assist

By Devika Patel

Knoxville, Tenn., June 18 – Nabriva Therapeutics AG will price its initial public sale of American Depositary Shares, according to a Form F-1 filed Thursday with the Securities and Exchange Commission. The deal will have a 30-day greenshoe option, and the company has registered up to $92 million of stock.

Leerink Partners and RBC Capital Markets are the bookrunning managers; Needham & Co. and Wedbush PacGrow are the co-managers.

Proceeds will be used for clinical development, working capital and other general corporate purposes.

The biopharmaceutical company is based in Vienna, Austria. It expects the ADSs to trade on the Nasdaq under the symbol “NBRV.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.